Lack of genetic evidence for NLRP3-inflammasome 1 involvement in Parkinson's disease pathogenesis 2

Konstantin Senkevich, MD, PhD, ^{1,2} Lang Liu MSc^{1,2,3}, Chelsea X. Alvarado^{4,5}, Hampton L. 3

Leonard, MSc, ^{4,5,6}, Mike A. Nalls, PhD, ^{4,5}; Global Parkinson's Genetics Program (GP2); Ziv 4 Gan-Or, MD. PhD^{1,2,3}

Author affiliations: 6

- 1. The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, 7 8 Ouebec, Canada
- 2. Department of Neurology and neurosurgery, McGill University, Montréal, QC, 9 10 Canada, Canada
- 3. Department of Human Genetics, McGill University, Montréal, QC, Canada 11
- 12 4. Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of 13 Health, Bethesda, MD, USA, 20814 14
- 5. Data Tecnica, Washington, DC, USA, 200373. 15
- 6. DZNE Tübingen, Tübingen, Germany 16
- 17

Abstract 18

19 Activation of the NLRP3-inflammasome has been implicated in Parkinson's disease based on 20 in vitro and in vivo studies. Clinical trials targeting the NLRP3-inflammasome in Parkinson's 21 disease are ongoing. However, the evidence supporting NLRP3's involvement in Parkinson's 22 disease from human genetics data is limited. In this study, we conducted analyses of common 23 and rare variants in NLRP3-inflammasome related genes in Parkinson's disease cohorts. We 24 performed pathway-specific analyses using polygenic risk scores and studied potential causal 25 associations using Mendelian randomization with the NLRP3 components and the cytokines 26 IL-1 β and IL-18. Our findings showed no associations of common or rare variants, nor of the 27 pathway polygenic risk score with Parkinson's disease. Mendelian randomization suggests 28 that altering the expression of the NLRP3-inflammasome, IL-1 β or IL-18, does not affect Parkinson's disease risk or progression. Therefore, our results do not support a role for the 29 30 NLRP3-inflammasome in Parkinson's disease pathogenesis or as a target for drug 31 development.

- Correspondence to: 32
- Ziv Gan-Or 33
- McGill University 34
- 35 1033 Pine Avenue, West, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁵

- 1 Ludmer Pavilion, room 312
- 2 Montreal, QC, H3A 1A1,
- 3 Phone: +1-514-398-5845
- 4 Fax. +1-514 398-8248
- 5 Email: <u>ziv.gan-or@mcgill.ca</u>
- 6
- 7 Keywords: Parkinson's disease, clinical trials, NLRP3, genetics, inflammation
- 8 **Running title:** NLRP3 genetics: Limited druggability in Parkinson's disease
- 9

1 Introduction

2 In recent years, activation of the nucleotide-binding oligomerization domain-, leucine-rich 3 repeat and pyrin domain-containing 3 (NLRP3) inflammasome has been implicated in Parkinson's disease by numerous functional studies using different models¹. Inflammasomes 4 5 are protein complexes which serve as signaling platforms for activation of immune response. 6 The NLRP3 inflammasome comprises three main components: NLRP3 (encoded by the 7 NLRP3 gene), apoptosis-associated speck-like protein containing a caspase activating 8 recruitment domain (encoded by PYCARD) and caspase-1 (CASP1). NLRP3 is expressed in 9 microglia and when activated, it leads to secretion of the cytokines IL-1 β and IL-18, which leads to neuroinflammatory response and pyroptosis². 10

The evidence for the involvement of the NLRP3 inflammasome in Parkinson's 11 12 disease is mainly derived from *in vitro* and *in vivo* cell and animal models, by interacting 13 with α -synuclein, mitochondria and other mechanisms. For example, early research suggested that in human monocytes, α -synuclein may directly trigger the NLRP3 inflammasome³. 14 Similar results have been reported in other cell and animal models^{4,5}. Other studies in cell 15 16 and animal models have suggested that the NLRP3 inflammasome may be involved in toxin-17 mediated Parkinson's disease and that there could be an interplay between mitochondria and the NLRP3 inflammasome in Parkinson's disease pathogenesis ^{6,7}. In humans, one study 18 reported that a genetic variant in NLRP3 may affect its expression and the risk of Parkinson's 19 disease⁸. Several studies in cells and postmortem brain tissues from Parkinson's disease 20 21 patients and controls reported alterations in the NLRP3 inflammasome in Parkinson's disease ⁸⁻¹⁰. However, there are no thorough human genetic studies of the NLRP3 inflammasome in 22 23 Parkinson's disease, although such studies can help with inferring causality. Nevertheless, 24 there is a suggestion that the NLRP3 inflammasome may be a good target for therapeutic 25 development in Parkinson's disease, and several compounds targeting the NLRP3 inflammasome are in different stages of development ¹¹. Considering that clinical trial 26

- 1 success rates increase significantly when supported by genetic evidence 1^{12} , it becomes crucial
- 2 to conduct thorough genetic analysis of the proposed target.
- In this study, we aimed to examine whether human genetics data supports NLRP3 involvement in Parkinson's disease and development of therapeutics targeting NLRP3 for Parkinson's disease. We analyzed common and rare variants in the NLRP3 inflammasome components in large Parkinson's disease cohorts, and further performed pathway specific analyses of polygenic risk scores (PRS) and Mendelian randomization (MR) analyses. Our results do not support an important role for the NLRP3 inflammasome in Parkinson's disease nor its being a good target for therapeutic development in sporadic Parkinson's disease.

1 **Results**

2 No association between NLRP3 inflammasome genes and

3 Parkinson's disease

4 We examined common variants from the largest available Parkinson's disease risk GWAS (N cases/proxy-cases= 49,053; N controls= 1,411,006)¹³. We did not observe any associations 5 6 between Parkinson's disease and variants in genes composing the NLRP3 complex (NLRP3, 7 *PYCARD* and *CASP1*) and the genes encoding the cytokines released by its activation, *IL-1* β 8 and IL-18 in neither GWAS on participants from European ancestry nor the diverse non-9 European Global Parkinson's Genetics Program (GP2) cohorts (Fig. 1; Supplementary Figure 10 1). While the *PYCARD* gene is located near one of the GWAS loci (rs11150601) within 11 SETD1A, PYCARD is just outside of the linkage disequilibrium (LD) block, i.e. there are no 12 variants within or in regulatory regions of *PYCARD* that are in LD ($r^{2}<0.2$) with the variants 13 that surpassed the GWAS level of significance. We then performed PRS analyses for the 14 three NLRP3 inflammasome genes from 14,828 Parkinson's disease cases and 13,283 15 controls across 7 cohorts (detailed in Supplementary Table 1). Overall, the PRS explains a 16 very small portion of the variance in Parkinson's disease (1.39E-06-0.001) and was not 17 associated with Parkinson's disease (Fig. 2, Supplementary Table 2).

We also analyzed rare variants in two independent cohorts, including 2,943 patients and 18,486 controls, followed by a meta-analysis (Supplementary Table 3). We did not observe any associations between any subsets of variants in any of the genes comprising the NLRP3 inflammasome and Parkinson's disease (Supplementary Table 4). We then performed an analysis including all the variants in all three genes combined, and in this analysis too, we did not observe any associations between rare variants and Parkinson's disease (Supplementary Table 4).

1 Mendelian randomization does not support NRLP3 as a

2 druggable target for Parkinson's disease.

3 Using summary-data-based Mendelian Randomization (SMR), we investigated whether the 4 modulation of the NLRP3 inflammasome could be a target for therapy. Initially, we established that NLRP3, CASP1, IL-1β, IL-18 are recognized within the database of 5 druggable genes, highlighting their potential relevance for drug development¹⁴. PYCARD, 6 7 however, did not meet these criteria. We than performed SMR, where exposure were Quantitative trait loci (QTL) of NLRP3 genes from tissues that are relevant to Parkinson's 8 9 disease pathogenesis. In the present study, we used the Genotype-Tissue Expression (GTEx) project v8 release (All brain tissues, blood and liver), PsychENCODE, and BrainMeta/brain-10 eMeta ¹⁵⁻¹⁷. As an outcome for SMR, we used the most recent Parkinson's disease risk ¹³, 11 12 Parkinson's disease age-at-onset ¹⁸ GWASs and largest publicly available Parkinson's disease motor and cognitive progression GWASs^{19,20}. Our analysis did not reveal any potential 13 causal associations between the QTL data tested in this study and Parkinson's disease in 14 15 tissues relevant for Parkinson's disease after correction for multiple comparisons 16 (Supplementary Table 5).

1 Discussion

Our results, using large-scale human genetic, transcriptomic and methylomic data, do not support the NLRP3 inflammasome as important in Parkinson's disease pathogenesis or as a good target for drug development. There were no associations of common or rare variants, nor of polygenic risk score for the NLRP3 inflammasome, with risk of Parkinson's disease. When we considered the three NLRP3 genes as druggable targets, there was no evidence that altering their expression at the RNA level may have an effect on risk, onset or Parkinson's disease progression.

9 While using MR to infer efficient druggability is not a definitive test, it can still 10 provide valuable information. For example, a recent MR study was able to replicate the 11 beneficial effects of tumor necrosis factor (TNF) inhibition in Crohn's disease and ulcerative 12 colitis, and its deleterious effect in multiple sclerosis ²¹. The same study also suggested that 13 TNF inhibition might not be beneficial for Parkinson's disease.

14 Understanding the role of a drug compound is essential when planning clinical trials. Studies that are not guided by genetic evidence are more likely to fail ¹². Currently, several 15 16 phase 1 clinical trials targeting neuroinflammation and particularly NLRP3-inflamassome are being conducted ²². The discordance between the hypothesis underlying these clinical trials 17 18 targeting NLRP3 pathway in Parkinson's disease and our findings suggests that efforts to 19 target the NLRP3 inflammasome in Parkinson's disease should be critically evaluated. It is 20 important to select therapeutic strategies based on robust human genetic and biomarker 21 evidence to reduce chances of trial failure. Perhaps targeting the NLRP3 inflammasome 22 could work specifically in individuals in which this pathway is pathologically activated, but 23 this approach is not being taken to the best of our knowledge. Subpopulations of patients with 24 distinct genetic or environmental risk factors where the NLRP3 pathway plays a role in 25 disease pathogenesis may exist. However, additional effort on defining subpopulation of 26 Parkinson's disease patients with neuroinflammation and particularly with induction of the

NLRP3 pathway should be considered in clinical research targeting the NLRP3
 inflammasome. Future studies exploring potential gene-environment interactions may further
 explain the role of the NLRP3 inflammasome in specific subsets of Parkinson's disease
 patients.

5 Our study has several limitations that need to be acknowledged. The GWASs on 6 Parkinson's disease progression that were used could be underpowered. Further analysis 7 using larger datasets should be performed when they become available to confirm our 8 findings. Another important limitation of our study is the reliance solely on genetic and 9 transcriptomic data to infer the role and druggability of the NLRP3 inflammasome in 10 Parkinson's disease. This approach does not account for post-translational modifications and 11 the complex regulation at the protein level, which are critical for the functional activity of the 12 NLRP3 inflammasome. Finally, the SMR analysis is dependent on the quality of the 13 expression data used for exposure, and variations in quality across datasets might influence the results. 14

In conclusion, our analyses do not provide human genetic evidence for the involvement of the NLRP3 inflammasome in Parkinson's disease, suggesting potentially limited druggability from genetic perspective.

1 Online Methods

2 Study populations

To examine whether common variants in the NLRP3 inflammasome components may be 3 associated with Parkinson's disease, we used summary statistics from the largest European 4 Parkinson's disease GWAS¹³ and also analyzed genes of interest using the data from GP2 5 6 (release six) in several ancestry populations (detailed in Supplementary Table 6). Quality 7 control analyses for both samples and variants have been previously described (https://github.com/GP2code/GenoTools). To study the association of common variants 8 9 (minor allele frequency > 1%) with Parkinson's disease in GP2 cohorts, we performed 10 logistic regression, adjusting for age, sex, and the top five principal components in each ancestral population. For each of the cohorts, we created locus zoom plots using locuszoomr 11 R library²³ for the NLRP3, CASP1, PYCARD, IL-1 β and IL-18, loci with +/- 500kb around 12 13 each gene. We then created pathway specific PRS for the NLRP3 inflammasome using 14 available individual level data from cohorts of European ancestry (detailed in Supplementary Table 1). 15

In our Mendelian randomization analysis, we utilized the following summary 16 statistics datasets: Parkinson's disease risk GWAS¹³, Parkinson's disease age-at-onset 17 GWAS with 17,415 cases ¹⁸, and Parkinson's disease progression data from GWAS studies 18 conducted by Iwaki et al.¹⁹ and Tan et al.²⁰. The Parkinson's disease progression traits in the 19 study by Iwaki et al.¹⁹ were measured using observational study meta-analysis of clinical 20 21 scales data, we specifically used UPDRS Part III (N cases = 1,398), MMSE (N cases = 1,329), and MoCA (N cases = 1,000) scores. In the study by Tan et al. 20 , Parkinson's disease 22 23 progression was assessed using scores for motor, cognitive, and composite progression in 24 3,364 Parkinson's disease patients with an average follow-up of 4.2 years.

To analyze rare variants, we performed analysis in two cohorts with available wholeexome and whole-genome sequencing data with a total of 2,943 Parkinson's disease patients and 18,486 controls (Supplementary Table 3). Whole-genome sequencing was available from the Accelerating Medicines Partnership – Parkinson Disease (AMP-PD) initiative cohorts (https://amp-pd.org/; detailed in the Acknowledgment). Whole-exome data was available from the UK biobank (UKBB) cohort which was accessed using Neurohub (https://www.mcgill.ca/hbhl/neurohub).

8 Polygenic risk score pathway analysis

9 In order to examine the potential genetic association of the NLRP3 complex as a whole in 10 Parkinson's disease (as opposed to analysis of specific SNPs), we calculated pathway PRS 11 using PRSet for the three genes encoding the components of the NLRP3 complex (NLRP3, *PYCARD* and *CASP1*)²⁴. In this analysis, we only included participants of European origin 12 13 and removed first- or second-degree relatives. Sex discrepancy analysis was conducted to 14 compare the recorded biological sex of individuals in the dataset with their genetically 15 inferred sex, determined by rates of heterozygosity and homozygosity on the X chromosome. 16 This analysis used the --check-sex function in PLINK 1.9, where males were expected to 17 exhibit an X chromosome homozygosity estimate greater than 0.85, and females less than 18 0.25. This method enabled the identification and exclusion of samples with potential sex 19 mismatches (where the reported sex at recruitment does not match the genetic sex), thereby 20 enhancing the accuracy of subsequent genetic analyses. Only common SNPs with minor 21 allele frequency > 0.01 and p-value < 0.05 were included in the analysis. We conducted LD 22 clumping, removing variants with $r^2 > 0.1$ and within a 250kb distance. We performed a 23 permutation test with 10000 repetitions to generate an empirical p-value for our gene set of 24 interest. We used age at onset for cases, age at enrollment for controls, sex, and the top 10 25 principal components as covariates.

26 Whole-exome and whole-genome sequencing data analysis

1 To determine whether rare variants in the genes encoding the components of the NLRP3 2 inflammasome (NLRP3, PYCARD and CASP1), we extracted genetic data from whole-exome 3 and whole-genome sequencing datasets. Our analysis included only participants of European 4 ancestry, and we excluded any first or second-degree relatives from the study. For wholegenome sequencing data, we performed quality control as previously described ²⁵. In brief, 5 6 we included samples with a mean coverage of 25x and a rate of missing genotypes per 7 sample less than 5%. For the UK Biobank's whole-exome sequencing data, we used the 8 Genome Analysis Toolkit (GATK, v3.8) to perform quality control. We applied the 9 recommended filtration parameters for whole-exome sequencing data, which included a minimum depth of coverage of 10x and a minimum genotype quality (GQ) score of 20²⁶. 10 11 The human reference genome hg38 was used for alignment.

We analyzed the association of rare variants with minor allele frequency <0.01 using the optimized sequence kernel association test (SKAT-O) ²⁷. The variants were grouped to different categories: all rare variants, all non-synonymous variants, loss-of-function variants (stop, frame-shift and canonical splice-site variants) and variants with a combined annotation dependent depletion (CADD) score \geq 20 (representing 1% of the top deleterious variants). To meta-analyze the two cohorts we used the metaSKAT R package ²⁸.

18 Mendelian randomization

19 If modulation of the NLRP3 inflammasome is a target for therapy, then genetically driven 20 differences in its expression, or that of the cytokines released following its activation, IL-1 β 21 and IL-18, should be causally linked to Parkinson's disease risk or progression. To examine this possibility, we used SMR. SMR utilizes summary-level data to determine whether a 22 23 causal relationship exists between an exposure and an outcome. In our specific case, we 24 examined if differences in expression levels of the NLRP3 genes (using quantitative trait loci, 25 QTL) are associated with risk, age-at onset and progression of Parkinson's disease. As 26 exposure, we used different QTL data from various studies and tissues including methylation,

1 gene-expression and chromatin QTLs. All the QTLs we used were collected from the same 2 resource, and we conducted analyses using SMR software developed by Yang Lab with standard settings (<u>https://yanglab.westlake.edu.cn</u>)^{29,30}. Specifically GTEx project v8 release 3 (All brain tissues, blood and liver), PsychENCODE, and BrainMeta/brain-eMeta¹⁵⁻¹⁷. As an 4 outcome for SMR, we used the most recent Parkinson's disease risk ¹³, Parkinson's disease 5 age-at-onset ¹⁸ GWASs and largest publicly available Parkinson's disease progression 6 7 GWASs^{19,20}. The Bonferroni-corrected significance threshold was set at p < 0.05/185=0.00027. 8

9 Data availability

10 All code is available on our GitHub repository, which can be accessed at 11 https://github.com/gan-orlab/NLRP3. The data used in the preparation of this article were 12 obtained from the AMP PD Knowledge Platform (https://www.amp-pd.org) and the UKBB 13 via Neurohub (https://www.mcgill.ca/hbhl/neurohub). The full GWAS summary statistics for 14 the 23andMe inc., discovery data set will be made available through 23andMe to qualified 15 researchers under an agreement with 23andMe that protects the privacy of the 23andMe 16 participants. Please visit research.23andme.com/collaborate/ for more information and to 17 apply to access the data. QTL data and SMR software are available on the Yang Lab website 18 (https://yanglab.westlake.edu.cn).

19

1 Acknowledgements

2 We would like to thank the participants in the different cohorts for contributing to this study. 3 ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheursboursiers award, in collaboration with Parkinson Quebec, and is a William Dawson Scholar. 4 5 The KS is supported by a clinical fellowship from the Parkinson Canada. Data used in the 6 preparation of this article were obtained from the AMP PD Knowledge Platform. For up-to-7 date information on the study, visit https://www.amp-pd.org. AMP PD – a public-private partnership - is managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox 8 9 Foundation for Parkinson's Research, the National Institute of Neurological Disorders and Stroke, Pfizer, Sanofi, and Verily. Genetic data used in preparation of this article were 10 11 obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the 12 Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), the 13 Parkinson's Disease Biomarkers Program (PDBP), the International LBD Genomics 14 Consortium (iLBDGC), and the STEADY-PD III Investigators. BioFIND is sponsored by 15 The Michael J. Fox Foundation for Parkinson's Research (MJFF) with support from the 16 National Institute for Neurological Disorders and Stroke (NINDS). The BioFIND 17 Investigators have not participated in reviewing the data analysis or content of the 18 manuscript. For up-to-date information on the study, visit michaeljfox.org/news/biofind. The 19 HBS is a collaboration of HBS investigators [full list of HBS investigators found at 20 https://www.bwhparkinsoncenter.org/biobank/ and funded through philanthropy and NIH and 21 Non-NIH funding sources. The HBS Investigators have not participated in reviewing the data 22 analysis or content of the manuscript. PPMI - a public-private partnership – is funded by the 23 Michael J. Fox Foundation for Parkinson's Research and funding partners, including [list the 24 full names of all of the PPMI funding partners found at www.ppmi-info.org/fundingpartners]. 25 The PPMI Investigators have not participated in reviewing the data analysis or content of the 26 manuscript. For up-to-date information on the study, visit www.ppmi-info.org. PDBP 27 consortium is supported by the NINDS at the National Institutes of Health. A full list of

1 PDBP investigators can be found at https://pdbp.ninds.nih.gov/policy. The PDBP 2 investigators have not participated in reviewing the data analysis or content of the 3 manuscript. Genome Sequencing in Lewy Body Dementia and Neurologically Healthy 4 Controls: A Resource for the Research Community." was generated by the iLBDGC, under 5 the co-directorship by Dr. Bryan J. Traynor and Dr. Sonja W. Scholz from the Intramural 6 Research Program of the U.S. National Institutes of Health. The iLBDGC Investigators have 7 not participated in reviewing the data analysis or content of the manuscript. For a complete 8 list of contributors, please see: bioRxiv 2020.07.06.185066; doi: 9 https://doi.org/10.1101/2020.07.06.185066. STEADY DD III is a 36 month, Phase 3, 10 parallel group, placebo controlled study of the efficacy of isradipine 10 mg daily in 336 11 participants with early Parkinson's Disease that was funded by the NINDS and supported by 12 The Michael J Fox Foundation for Parkinson's Research and the Parkinson's Study Group. 13 The STEADY-PD III Investigators have not participated in reviewing the data analysis or 14 content of the manuscript. The full list of STEADY PD III investigators can be found at: https://clinicaltrials.gov/ct2/show/NCT02168842. We would also like to thank the research 15 16 participants and employees of 23andMe, inc. for making this work possible. The full GWAS 17 summary statistics for the 23andMe discovery data set will be made available through 18 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy 19 of the 23andMe participants. Please visit research.23andme.com/collaborate/ for more 20 information and to apply to access the data. This research used the NeuroHub infrastructure 21 and was undertaken thanks in part to funding from the Canada First Research Excellence 22 Fund, awarded through the Healthy Brains, Healthy Lives initiative at McGill University, 23 Calcul Québec and Compute Canada. This research has been conducted using the UK 24 Biobank Resource under Application Number 45551. The UKBB cohort was accessed using 25 Neurohub (https://www.mcgill.ca/hbhl/neurohub). This research was supported in part by the 26 Intramural Research Program of the NIH, National Institute on Aging (NIA), National 27 Institutes of Health, Department of Health and Human Services; project number

ZIAAG000535, as well as the National Institute of Neurological Disorders and Stroke. This work utilized the computational resources of the NIH HPC Biowulf cluster. (http://hpc.nih.gov). Data used in the preparation of this article were obtained from Global Parkinson's Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org). The members of the GP2 groups are listed in the supporting information. For a complete list of GP2 members see https://gp2.org.

8 Funding

9 This work was financially supported by grants from the Michael J. Fox Foundation, the
10 Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research
11 Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy
12 Lives initiative (HBHL), and Parkinson Canada.

13 Competing interests

Z.G.O received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanquabio Guidepoint, Lighthouse and Deerfield. C.X.A., M.A.N. and HL.L.'s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc. and as an advisor to Neuron23 Inc.

1 Supplementary material

- 2 Supplementary Table 1. Study population for pathway specific PRS analysis of NLRP3
- 3 inflammasome genes
- 4 Supplementary Table 2. Pathway specific polygenic risk score analysis on the of NLRP3
- 5 inflammasome in Parkinson's disease
- 6 Supplementary Table 3. Study population for rare variant analysis
- 7 Supplementary Table 4. Burden analysis of rare variants in NLRP3 inflammasome related
- 8 genes
- 9 Supplementary Table 5. Summary based Mendelian randomization studies between NLRP3
- 10 related genes expression loci and Parkinson's disease risk and progression
- 11 Supplementary Table 6. GP2 study population for the role of common variants in NLRP3
- 12 inflammasome genes

1 References

2 1. Jewell, S., Herath, A.M. & Gordon, R. Inflammasome Activation in Parkinson's Disease. J 3 Parkinsons Dis 12, S113-s128 (2022). 4 2. Haque, M.E., et al. Targeting the microglial NLRP3 inflammasome and its role in Parkinson's 5 disease. Mov Disord 35, 20-33 (2020). 6 3. Codolo, G., et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory 7 response in synucleinopathies. *PloS one* 8, e55375 (2013). 8 Gustot, A., et al. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's 4. disease. Biochem J 471, 323-333 (2015). 9 10 5. Shao, Q.H., Zhang, X.L., Yang, P.F., Yuan, Y.H. & Chen, N.H. Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome. Int 11 12 Immunopharmacol 49, 155-160 (2017). 13 6. Mao, Z., et al. The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's 14 Disease in Rats. Neurochem Res 42, 1104-1115 (2017). 7. Sarkar, S., et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome 15 16 proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ 17 Parkinsons Dis 3, 30 (2017). 18 8. von Herrmann, K.M., et al. NLRP3 expression in mesencephalic neurons and characterization 19 of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease. NPJ 20 Parkinsons Dis 4, 24 (2018). 9. 21 Fan, Z., et al. Systemic activation of NLRP3 inflammasome and plasma α -synuclein levels are 22 correlated with motor severity and progression in Parkinson's disease. J Neuroinflammation 23 **17**, 11 (2020). 24 10. Anderson, F.L., et al. Plasma-borne indicators of inflammasome activity in Parkinson's 25 disease patients. NPJ Parkinsons Dis 7, 2 (2021). 26 Nguyen, L.T.N., et al. Role of NLRP3 Inflammasome in Parkinson's Disease and Therapeutic 11. 27 Considerations. J Parkinsons Dis 12, 2117-2133 (2022). 28 12. Minikel, E.V., Painter, J.L., Dong, C.C. & Nelson, M.R. Refining the impact of genetic evidence 29 on clinical success. medRxiv, 2023.2006.2023.23291765 (2023). 30 13. Nalls, M.A., et al. Identification of novel risk loci, causal insights, and heritable risk for 31 Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet 32 Neurology 18, 1091-1102 (2019). 33 14. Finan, C., et al. The druggable genome and support for target identification and validation in 34 drug development. Sci Transl Med 9(2017). 35 Consortium, G. The GTEx Consortium atlas of genetic regulatory effects across human 15. 36 tissues. Science 369, 1318-1330 (2020). 37 16. Wang, D., et al. Comprehensive functional genomic resource and integrative model for the 38 human brain. Science 362, eaat8464 (2018). 39 17. Qi, T., et al. Identifying gene targets for brain-related traits using transcriptomic and 40 methylomic data from blood. Nature communications 9, 2282 (2018). 41 18. Blauwendraat, C., et al. Parkinson's disease age at onset genome-wide association study: 42 Defining heritability, genetic loci, and α -synuclein mechanisms. Mov Disord **34**, 866-875 43 (2019). 44 19. Iwaki, H., et al. Genomewide association study of Parkinson's disease clinical biomarkers in 45 12 longitudinal patients' cohorts. Mov Disord 34, 1839-1850 (2019). 46 20. Tan, M.M.X., et al. Genome-Wide Association Studies of Cognitive and Motor Progression in 47 Parkinson's Disease. Mov Disord 36, 424-433 (2021). 21. 48 Kang, X., et al. Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian 49 Randomization Study. Neurology 96, e1672-e1679 (2021). 50 22. McFarthing, K., et al. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 51 Update. J Parkinsons Dis 13, 427-439 (2023). 52 23. Pruim, R.J., et al. LocusZoom: regional visualization of genome-wide association scan results. 53 Bioinformatics 26, 2336-2337 (2010). 54 24. Choi, S.W., et al. PRSet: Pathway-based polygenic risk score analyses and software. PLoS 55 genetics 19, e1010624 (2023).

1	25.	lwaki, H., et al. Accelerating medicines partnership: Parkinson's disease. genetic resource.
2		Movement Disorders 36 , 1795-1804 (2021).
3	26.	Carson, A.R., et al. Effective filtering strategies to improve data quality from population-
4		based whole exome sequencing studies. BMC Bioinformatics 15, 125 (2014).
5	27.	Lee, S., et al. Optimal unified approach for rare-variant association testing with application
6		to small-sample case-control whole-exome sequencing studies. The American Journal of
7		Human Genetics 91 , 224-237 (2012).
8	28.	Lee, S., Teslovich, T.M., Boehnke, M. & Lin, X. General framework for meta-analysis of rare
9		variants in sequencing association studies. The American Journal of Human Genetics 93, 42-
10		53 (2013).
11	29.	Zhu, Z., et al. Integration of summary data from GWAS and eQTL studies predicts complex
12		trait gene targets. <i>Nature genetics 48,</i> 481-487 (2016).
13	30.	Wu, Y., et al. Integrative analysis of omics summary data reveals putative mechanisms
14		underlying complex traits. Nature communications 9, 918 (2018).
15		



- Figure 1. Locus zoom plot of NLRP3, CASP1, PYCARD, IL-1 β and IL-18 genes (+/- 500
- 4 kb) in Parkinson's disease GWAS.
- 5 The SNP with the lowest P-value in the studied gene or locus is highlighted by red square.

6 The punctuated line represents GWAS level of significance $p < 5 \times 10^{-8}$. SNPs shown in grey

7 are below this significance level, while those in blue exceed it. X-axis: Chromosomal

8 position (in Mb). Y-axis: Negative log10 of the P-values from GWAS.



9

1

10 Figure 2. Pathway specific PRS analysis of NLRP3 inflammasome genes.

OR- odds ratio; CI- confidence interval; PPMI- Parkinson's Progression Markers Initiative;
 APDGC- Autopsy-Confirmed Parkinson Disease GWAS Consortium; IPDGC -International
 Parkinson Disease Genomics Consortium; NINDS- National Institute of Neurological
 Disorders and Stroke Repository Parkinson's Disease Collection, NGRC- NeuroGenetics
 Research Consortium; UKBB-UK Biobank